Aster DM Healthcare Limited is a significant and diversified healthcare services organization. The company operates a comprehensive network of facilities, including hospitals, clinics, diagnostic labs, and pharmacies, primarily concentrated in the southern and western regions of India. As of December 2025, its presence spans 16 cities across five states, with a notable footprint in Kerala, Karnataka, Maharashtra, Andhra Pradesh, and Telangana. The company's core business is its hospital network, which comprises 20 hospitals with a total capacity of over 5,400 beds. This network is strategically segmented into geographical clusters, with Kerala being the largest contributor to revenue. Aster DM is pursuing a significant merger with Quality Care India Limited (QCIL), which will create a combined entity with 39 hospitals, over 10,600 beds, and a presence in 28 cities, establishing it as one of India's largest hospital networks. The company's leadership, under Founder Chairman Dr. Azad Moopen and Deputy Managing Director Alisha Moopen, is heavily decorated with industry awards, reflecting a strong reputation for vision and execution in the healthcare sector. Aster DM emphasizes clinical excellence, leveraging advanced medical technology such as robotic surgery systems and digital imaging to deliver high-quality patient care across a balanced mix of specialties, ensuring no single discipline dominates its revenue stream. The company is also advancing its digital capabilities through initiatives like the "Aster Health" app to create an integrated "phygital" ecosystem, enhancing patient access and engagement.

Official Website: http://www.asterdmhealthcare.com/

• Combined Proforma Performance (Aster + QCIL) for Q3 FY26:

• Revenue from Operations: Grew 15% year-over-year (YoY) to INR 2,366 crores, up from INR 2,057 crores in Q3 FY25. This growth was driven by a 9% YoY increase in total patient volumes.

• Operating EBITDA: Increased by a robust 22% YoY to INR 503 crores. Excluding the newly operationalized Kasargod hospital, the growth was even stronger at 25% YoY.

• Net Debt: The combined entity holds a net debt of INR 953 crores.

• Aster Standalone Performance for Q3 FY26:

• Revenue from Operations: Grew 13% YoY to INR 1,186 crores. The core hospital and clinics business saw revenue growth of 15% YoY (14% ex-Kasargod).

• Operating EBITDA: Increased 11% YoY to INR 224 crores. Excluding the new Kasargod facility, Operating EBITDA grew 17% YoY to INR 237 crores.

• Normalised Profit After Tax (PAT): Remained flat at INR 81 crores compared to the prior year's quarter. However, excluding Kasargod, Normalised PAT grew 22% YoY to INR 98 crores.

• Return on Capital Employed (RoCE): Improved to 21.0% from 19.5% in Q3 FY25, indicating more efficient use of capital.

• QCIL Standalone Performance for Q3 FY26:

• Revenue: Grew 17% YoY to INR 1,181 crores, driven by higher inpatient volumes and an improved payor mix.

• Operating EBITDA: Showed significant growth of 32% YoY to INR 279 crores, attributed to topline growth and operational efficiencies.

• Return on Capital Employed (RoCE): Increased to 20.5% from 18.6% in the previous year.

The company demonstrates strong top-line and operating profit growth, both on a standalone and combined proforma basis, with improving returns on capital.

• Diversified and Balanced Specialty Mix:

• The company maintains a well-balanced revenue stream from its various medical specialties. In Q3 FY26, the top contributors were Cardiac Sciences (15%), Neurosciences (11%), and Oncology (11%).

• Crucially, no single specialty accounts for more than 15% of total revenue, which reduces dependence on any one area and provides a stable operational base.

• Focus on High-End Procedures and Clinical Excellence:

• Aster is committed to advancing clinical capabilities, evidenced by numerous milestones such as performing the first Transcatheter Fontan procedure in Kerala and the first robotic cancer surgery in its district's private sector.

• The company has performed over 2,400 robotic surgeries and over 560 transplants on a trailing twelve-month basis, indicating a strong focus on high-acuity, complex medical procedures.

• Integrated "Phygital" Ecosystem:

• The company is actively building an integrated healthcare platform that combines physical infrastructure with digital access.

• The "Aster Health" App, with over 350,000 downloads, serves as a key patient engagement tool, enabling access to services and medical records, thereby creating a scalable, data-driven growth engine.

• Proven Asset Maturity Model:

• The company's hospitals demonstrate a clear path to profitability based on maturity. Hospitals operational for over 7 years achieved a robust Operating EBITDA margin of 25.1% in Q3 FY26.

• This model provides a predictable trajectory for newer hospitals, like the Kasargod facility, to contribute meaningfully to profitability as they scale.

Aster's strength lies in its diversified specialty mix, focus on high-margin clinical procedures, and a forward-looking strategy that integrates digital tools with its physical network.

• Revenue and Profitability Growth:

• The combined Aster + QCIL entity reported 15% YoY revenue growth and 22% YoY EBITDA growth in Q3 FY26.

• Aster's standalone revenue grew 13% YoY, driven by a 20% YoY increase in the Kerala cluster. QCIL's standalone revenue grew 17% YoY. This consistent, double-digit growth across entities underscores strong market demand and operational execution.

• Volume and Pricing Growth:

• Total patient volumes for the combined entity grew 9% YoY in Q3 FY26. Aster's standalone patient volume grew 10% YoY.

• Average Revenue Per Occupied Patient (ARPP IP) for Aster rose 9% YoY, driven by an improved specialty mix. QCIL's ARPP IP grew 8% YoY due to a better payor mix and increased share of complex procedures.

• Key Growth Drivers:

• Medical Value Travel (MVT): Revenue from international patients grew by a significant 41% YoY for Aster, led by a 64% YoY surge in its Kerala cluster.

• Oncology: This high-value specialty saw revenue growth of 27% YoY, increasing its contribution to total revenue from 10% to 11%.

• CONGO Mix: The contribution from high-margin specialties (Cardiology, Oncology, Neurology, Gastroenterology, Orthopedics) increased by 240 basis points to 52.4%, directly enhancing profitability.

• Strategic Growth Initiatives:

• The company's strategy focuses on enhancing niche specialties, optimizing payor mix, and expanding its ecosystem with labs and pharmacies to drive future growth.

The company's growth is multi-faceted, stemming from rising patient volumes, higher pricing power in complex procedures, and targeted expansion in high-potential segments like medical tourism and oncology.

• Post-Merger Synergies:

• The merger with QCIL is expected to unlock significant value, with a near-term EBITDA upside potential of 10-15% of the merged entity's FY24 proforma EBITDA.

• Revenue Synergies: Opportunities exist to expand international patient initiatives across the combined network and leverage integrated operations for better coverage with insurance companies.

• Supply Chain and Cost Synergies: Centralizing procurement of drugs and consumables is projected to rationalize spending. QCIL has already delivered over INR 20 crore of EBITDA uplift in Q3 FY26 from procurement synergies.

• Operational Synergies: The merger will create a broader base of senior specialists, enhance the ability to attract top medical talent, and allow for the optimization of corporate functions and overheads.

The merger with QCIL presents a clear opportunity to generate substantial cost and revenue synergies, driving improved profitability and operational scale.

• Current Capacity and Utilization:

• As of December 31, 2025, the combined entity (Aster + QCIL) has a capacity of 10,620+ beds across 39 hospitals.

• Aster's standalone capacity is 5,451 beds, with an overall occupancy rate of 61% in Q3 FY26. Mature hospitals (over 7 years) operate at a higher occupancy of 68%.

• QCIL's standalone capacity is 5,170+ beds, with an occupancy rate of 64% in Q3 FY26.

• Aggressive Expansion Pipeline:

• The company has a clearly defined plan to add over 4,080 beds in the coming years, which will bring the total capacity of the merged entity to over 14,710 beds.

• The expansion is phased: 234 beds in FY26, 944 beds in FY27, 1,877 beds in FY28, and 1,030 beds beyond FY28.

• Expansion Strategy (Brownfield vs. Greenfield):

• The expansion is a balanced mix of brownfield (expanding existing facilities) and greenfield (new projects). 54% of the new beds will be added to existing facilities, which typically offers a faster path to profitability.

• Key greenfield projects include Aster Capital in Trivandrum (454 beds) and Aster W&C in Hyderabad (300 beds).

• Major brownfield expansions are planned for Aster CMI (350 beds) and Aster Whitefield (159 beds) in Bengaluru.

The company is executing a significant, well-structured capex plan to expand its bed capacity by nearly 40%, balancing lower-risk brownfield projects with strategic greenfield investments to solidify its market leadership.

• Merger Implementation:

• The primary focus is the successful completion of the merger with QCIL, which is expected in Q1 FY27.

• Key regulatory milestones have been achieved, including approvals from CCI and SEBI. The company has filed its application with the NCLT, and a shareholder meeting is scheduled between February 27 and March 13, 2026.

• Network Expansion:

• The company is committed to its capital investment plan to add over 4,080 beds, creating one of India's largest hospital networks.

• The expansion will strengthen its leadership position in key markets like Bengaluru, where planned additions will bring its total capacity to over 2,900 beds.

• Strategic Priorities:

• Operational Efficiency: Continue to optimize existing facilities by improving payor mix and focusing on high-end procedures to drive better ARPOB.

• Cost Optimization: Enhance efficiency to lower operational expenses and improve EBITDA margins.

• Technology & Digital: Leverage technology and digital platforms like the Aster Health app to improve patient outcomes and expand reach.

• Continuity of Care: Build a comprehensive 360-degree ecosystem by integrating labs and pharmacies with the core hospital business.

The company's future is centered on completing the transformative merger with QCIL, executing its large-scale capacity expansion, and driving operational efficiencies through strategic and digital initiatives.

• Combined Entity Margin Profile:

• The proforma combined entity (Aster + QCIL) reported an Operating EBITDA margin of 21.3% in Q3 FY26, an improvement from 20.1% in Q3 FY25. This demonstrates the strong profitability profile of the merged business.

• Standalone Margin Performance:

• Aster: Reported an Operating EBITDA margin of 18.9% in Q3 FY26. Excluding the new Kasargod hospital, which is in its ramp-up phase, the margin was a healthier 20.2%.

• QCIL: Delivered a strong Operating EBITDA margin of 23.7% in Q3 FY26, a significant improvement of 265 basis points from 21.0% in the prior year, highlighting effective cost management.

• Margin Drivers and Segmentation:

• Hospital Maturity: Mature hospitals (over 7 years) are the most profitable segment for Aster, with an Operating EBITDA margin of 25.1%.

• Geographic Clusters: The Kerala cluster is a key profit center for Aster, with an Operating EBITDA margin of 22.9% (25.4% ex-Kasargod).

• Business Segments: Aster's core Hospitals and Clinics business operated at a 21.4% margin, while the Labs business improved its margin to 10.5%.

The company is demonstrating healthy and improving profitability margins, with the combined entity achieving over 21%, driven by strong performance at mature facilities and effective cost controls.

• Merger Progress:

• The merger with QCIL is proceeding as planned. The company has received a no-objection letter from stock exchanges and SEBI and has filed its application with the NCLT on December 11, 2025.

• The completion of the merger is anticipated in the first quarter of fiscal year 2027.

• New Hospital Ramp-Up (Aster MIMS Kasargod):

• The new 263-bed hospital in Kasargod became operational in Q3 FY26 and is showing strong early traction.

• In its first quarter, the hospital generated INR 10 crores in revenue, treating over 1,100 inpatients and 17,500 outpatients, validating the demand in its catchment area.

• Awards and Industry Recognition:

• The company and its leadership continue to receive widespread recognition. Dr. Azad Moopen was awarded "Legend in the Healthcare Industry" at FICCI Heal 2025, and Ms. Alisha Moopen was named "Dynamic Entrepreneur of the Year" at the Entrepreneur India Awards 2025.

• Aster Hospitals secured multiple top rankings, with Aster MIMS Calicut named the #1 Best Multispecialty Hospital by The Week India Health Summit 2025.

The merger process is on track for completion, new assets are ramping up successfully, and the company continues to build its brand equity through numerous industry accolades.